GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Update

GeoVax Labs Inc. (NASDAQ:GOVX) was the target of a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 321,661 shares, a growth of 112.3% from the January 15th total of 151,504 shares. Approximately 18.7% of the company’s shares are sold short. Based on an average daily volume of 201,570 shares, the short-interest ratio is currently 1.6 days. Based on an average daily volume of 201,570 shares, the short-interest ratio is currently 1.6 days. Approximately 18.7% of the company’s shares are sold short.

GeoVax Labs Stock Down 27.3%

Shares of GOVX opened at $1.68 on Friday. The business’s 50-day moving average price is $4.40 and its 200-day moving average price is $11.40. GeoVax Labs has a twelve month low of $1.63 and a twelve month high of $47.13. The stock has a market cap of $2.90 million, a PE ratio of -0.05 and a beta of 3.77.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($7.75) EPS for the quarter, missing the consensus estimate of ($6.00) by ($1.75). GeoVax Labs had a negative net margin of 403.88% and a negative return on equity of 489.67%. Analysts expect that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Wall Street Zen cut GeoVax Labs to a “strong sell” rating in a research note on Saturday, January 17th. D. Boral Capital reiterated a “buy” rating on shares of GeoVax Labs in a report on Wednesday, January 21st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $187.50.

Hedge Funds Weigh In On GeoVax Labs

Several hedge funds and other institutional investors have recently modified their holdings of GOVX. Jane Street Group LLC purchased a new position in GeoVax Labs during the 1st quarter valued at about $27,000. Hudson Bay Capital Management LP bought a new stake in shares of GeoVax Labs during the 3rd quarter valued at about $47,000. HRT Financial LP purchased a new stake in GeoVax Labs during the fourth quarter valued at approximately $31,000. Armistice Capital LLC bought a new position in GeoVax Labs in the 3rd quarter worth $253,000. Finally, Renaissance Technologies LLC purchased a new position in shares of GeoVax Labs during the 4th quarter valued at about $104,000. 6.09% of the stock is owned by institutional investors.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.